Last reviewed · How we verify
AM0010
AM0010 is a small molecule that targets the SGLT2 receptor.
AM0010 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AM0010 |
|---|---|
| Also known as | LY3500518, Pegilodecakin |
| Sponsor | Eli Lilly and Company |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the SGLT2 receptor, AM0010 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (PHASE1)
- Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (PHASE2)
- Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (PHASE3)
- Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (PHASE2)
- An Expanded Access Program for AM0010 (Pegilodecakin)
- A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants (PHASE1)
- A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (PHASE1)
- A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AM0010 CI brief — competitive landscape report
- AM0010 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI